Buildit: The problem is not with me, the problem is with GNBT. It should not be up to the investors to research an active initiative of a public company, in fact, there is nothing about GNBT that has been disseminated for nine months. Even those who have closely followed this company are 99.9% in the dark and no one knows anything about the financials. Why would one, unless so inclined to do so, want to waste their time trying to follow the tracks of a bear that were left nine months ago. I was simply encouraging someone who has the devotion, interest and time to do so, not on my behalf, but just more of curiosity at this point. We can expect no fair and open communications from the parent company, if it is still viable and we do not know if this NGB is still held by the parent. Thanks for checking the financial statement that this NGB may be a legitimate subsidiary. If has any legs, great, but I would expect if it does, it will or has been spun off. The financials are not current.
(2)
(1)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links